ram; (f) Sertraline. Table S1: Displaying begin and stop positions employed to extract relevant genetic data from full UKB sample. Table S2: Frequencies of CYP2C19 diplo-types and metabolic phenotypes in 33,149 Biobank participants taking antidepressants or antipsychotics. Table S3: Frequencies of CYP2D6 diplo-types and metabolic phenotypes in 33,149 Biobank participants taking antidepressants or antipsychotics. Table S4: HbA1c levels and CYP phenotypes across individual and groups of medicines. Table S5: Characteristics of CYP2C19 metabolic phenotype in our sample. Table S6: Characteristics of CYP2D6 metabolic phenotype in our sample. Table S7: CYP2D6 metabolic phenotypes of people today taking antidepressants. Table S8: CYP2C19 metabolic phenotypes of people today taking antidepressants. Table S9: CYP2D6 metabolic phenotype of people taking antipsychotics. Table S10: Association amongst CYP2D6 metabolic phenotype and HbA1c inside people taking paroxetine–Additional detail. Table S11: Association amongst CYP2D6 metabolic phenotype and HbA1c within men and women taking fluoxetine–additional detail. Table S12: Association between CYP2D6 metabolic phenotype and HbA1c within individuals taking venlafaxine–additional detail. Table S13: Association between CYP2C19 metabolic phenotype and HbA1c within people taking citalopram. Table S14: Stratified analysis of persons taking citalopram. Table S15: Association among CYP2C19 metabolic phenotype and HbA1c inside men and women taking sertraline. Table S16: Stratified evaluation of people today taking sertraline. Table S17: Association in between CYP2D6 and CYP2C19 metabolic phenotype and HbA1c within Amitriptyline. Table S18: Stratified evaluation of persons taking amitriptyline. Table S19: Association involving CYP2D6 and CYP2C19 metabolic phenotype and HbA1c within men and women taking tricyclic antidepressants. Table S20: Stratified evaluation of persons taking tricyclic antidepressants. Table S21: Antipsychotics regression model. Association among CYP2D6 metabolic phenotype and HbA1c–additional detail. Table S22: Association among CYP2D6 metabolic phenotype and HbA1c amongst participants taking only antipsychotics, without a co-prescribed antidepressant. Author Contributions: Conceptualization, I.A.-Z., M.W. and E.B.; methodology, I.A.-Z., M.W., H.I. and E.B.; formal evaluation, I.A.-Z., M.W., H.I.; investigation, I.A.-Z., M.W., H.I.; information curation, I.A.-Z., S.D., G.F., C.F. and J.H.-S.; writing–original draft preparation, I.A.-Z. and M.W.; writing–review and editing, All; visualization, I.A.-Z.; supervision, I.A.-Z., A.M. and E.B.; project Dopamine Receptor Agonist Source administration, I.A.-Z., A.M. and E.B.; funding acquisition, I.A.-Z., A.M. and E.B. All authors have read and Caspase 4 Inhibitor supplier agreed towards the published version in the manuscript. Funding: This study was supported by Healthcare Research Council doctoral studentships awarded to Isabelle Austin-Zimmerman, Anjali Bhat, and Jasmine Harju-Sepp en. Baihan Wang was supported by the China Scholarship Council-University College London Joint Research Scholarship. Haritz Irizar has received funding from the European Union’s Horizon 220 investigation and innovation programme un-der the Marie Sklodowska-Curie grant agreement no 747429 and is presently supported by a grant from the National Institute of Allergy and Infectious Diseases, National Institutes of Well being. Spiros Denaxas is supported by the NIHR Biomedical Study Centre at University College London Hospital NHS Trust, an Alan Turing Fellowship (EP/N51012